Summary
NAD+ precursor nicotinamide riboside (NR) has emerged as a promising compound to improve obesity-associated mitochondrial dysfunction and metabolic syndrome in mice. However, most short-term clinical trials conducted so far have failed to report positive outcomes. Therefore, we aimed to determine whether long-term NR supplementation boosts mitochondrial biogenesis and metabolic health in humans. Twins from 22 BMI-discordant monozygotic pairs were supplemented with an escalating dose of NR (250-1000 mg/day) for 5 months (clinicaltrials.gov entry NCT03951285). NR improved blood and tissue NAD+ metabolism, muscle mitochondrial number, myoblast differentiation and gut microbiota composition independent of BMI. NR also showed a capacity to modulate epigenetic control of gene expression in muscle and adipose tissue. However, NR did not ameliorate adiposity or metabolic health. Overall, our results suggest that NR acts as a potent modifier of NAD+ metabolism, muscle mitochondrial biogenesis and stem cell function, gut microbiota, and DNA methylation in humans irrespective of BMI.
Competing Interest Statement
C.B. is the inventor of intellectual property on the nutritional and therapeutic uses of NR. He serves as chief scientific advisor of ChromaDex, which licensed, developed, and commercialized NR technologies, and holds stock in ChromaDex. The other authors declare no competing interests.
Clinical Trial
NCT03951285
Funding Statement
The study was supported by Centre of Excellence funding from the Academy of Finland (272376 KHP and 336823 JK), as well as the Academy of Finland grants (286359 and 314455 EP, 335443, 314383, 272376 and 266286 KHP, 297908 and 328685 MO), the Sigrid Juselius Foundation, the Finnish Medical Foundation, the Medical Society of Finland, the Finnish Diabetes Research Foundation, the Novo Nordisk Foundation (NNF20OC0060547, NNF17OC0027232, NNF10OC1013354), the Gyllenberg Foundation, the Orion Research Foundation, the Biomedicum Helsinki Foundation, Government Research Funds (Helsinki University Hospital). This research was also supported by the Academy of Finland Profi6 336449 funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the Helsinki University Central Hospital (protocol number 270/13/01/2008) and the study was conducted according to the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵18 Lead contact
Data Availability
All data are part of the Twin Study and are deposited with the Biobank of the Finnish Institute for Health and Welfare (https://thl.fi/en/web/thl-biobank/for-researchers/sample-collections/twin-study). For details on accessing the data, see https://thl.fi/en/web/thl-biobank/for-researchers/application-process. All bona fide researchers can apply for the data.
